| Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England E Volz, S Mishra, M Chand, JC Barrett, R Johnson, L Geidelberg, ... Nature 593 (7858), 266-269, 2021 | 1132 | 2021 |
| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1106 | 2021 |
| SARS-CoV-2 evolution during treatment of chronic infection SA Kemp, DA Collier, RP Datir, IATM Ferreira, S Gayed, A Jahun, ... Nature 592 (7853), 277-282, 2021 | 967 | 2021 |
| SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo YJ Hou, S Chiba, P Halfmann, C Ehre, M Kuroda, KH Dinnon III, SR Leist, ... Science 370 (6523), 1464-1468, 2020 | 942 | 2020 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 842 | 2022 |
| Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies DA Collier, A De Marco, IATM Ferreira, B Meng, RP Datir, AC Walls, ... Nature 593 (7857), 136-141, 2021 | 708 | 2021 |
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity EC Thomson, LE Rosen, JG Shepherd, R Spreafico, A da Silva Filipe, ... Cell 184 (5), 1171-1187. e20, 2021 | 568 | 2021 |
| Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer DJ Pinato, S Howlett, D Ottaviani, H Urus, A Patel, T Mineo, C Brock, ... JAMA oncology 5 (12), 1774-1778, 2019 | 499 | 2019 |
| SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway BJ Willett, J Grove, OA MacLean, C Wilkie, G De Lorenzo, W Furnon, ... Nature microbiology 7 (8), 1161-1179, 2022 | 467 | 2022 |
| Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 438 | 2021 |
| A robust and efficient method for Mendelian randomization with hundreds of genetic variants S Burgess, CN Foley, E Allara, JR Staley, JMM Howson Nature communications 11 (1), 376, 2020 | 420 | 2020 |
| Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 363 | 2021 |
| The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma DJ Pinato, R Sharma, E Allara, C Yen, T Arizumi, K Kubota, D Bettinger, ... Journal of hepatology 66 (2), 338-346, 2017 | 362 | 2017 |
| Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients P Willeit, L Tschiderer, E Allara, K Reuber, L Seekircher, LU Gao, X Liao, ... Circulation 142 (7), 621-642, 2020 | 335 | 2020 |
| Polygenic basis and biomedical consequences of telomere length variation V Codd, Q Wang, E Allara, C Musicha, S Kaptoge, S Stoma, T Jiang, ... Nature genetics 53 (10), 1425-1433, 2021 | 223 | 2021 |
| Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic B Jackson, MF Boni, MJ Bull, A Colleran, RM Colquhoun, AC Darby, ... Cell 184 (20), 5179-5188. e8, 2021 | 218 | 2021 |
| Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19 L Gaziano, C Giambartolomei, AC Pereira, A Gaulton, DC Posner, ... Nature medicine 27 (4), 668-676, 2021 | 161 | 2021 |
| RETRACTED: Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses E Sofianopoulou, SK Kaptoge, S Afzal, T Jiang, D Gill, TE Gundersen, ... The Lancet Diabetes & Endocrinology 9 (12), 837-846, 2021 | 137 | 2021 |
| Are mass-media campaigns effective in preventing drug use? A Cochrane systematic review and meta-analysis E Allara, M Ferri, A Bo, A Gasparrini, F Faggiano BMJ open 5 (9), e007449, 2015 | 130 | 2015 |
| Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant P Elliott, D Haw, H Wang, O Eales, CE Walters, KEC Ainslie, C Atchison, ... Science 374 (6574), eabl9551, 2021 | 125 | 2021 |
